| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701493 | Journal of Thoracic Oncology | 2017 | 33 Pages |
Abstract
Smoking history predicted for efficacy with a veliparib-chemotherapy combination; toxicity was acceptable regardless of smoking history. A prespecified analysis of recent smokers is planned for ongoing phase 3 studies of veliparib in NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Martin MD, PhD, Normand MD, Erzsebet MD, Vera MD, C. Michael MD, Laszlo MD, Sergey MD, PhD, Fabrice MD, PhD, Ebenezer MD, Ulrich MD, Qin MS, Jiang PhD, Caroline MSc, Juliann MBA, Hao PhD, Rajendar K. PhD, Martin PhD, Peter PhD, Suresh S. MD,